Use of balloon expandable transcatheter valves for valve-in-valve implantation in patients with degenerative stentless aortic bioprostheses: Technical considerations and results  by Bapat, Vinayak et al.
Bapat et al Acquired Cardiovascular DiseaseUse of balloon expandable transcatheter valves for valve-in-valve
implantation in patients with degenerative stentless aortic
bioprostheses: Technical considerations and resultsVinayak Bapat, FRCS, CTh, William Davies, FRCP, Rizwan Attia, MRCS, Jane Hancock, FRCP,
Kirsty Bolter, MSc, Christopher Young, FRCS, CTh, Simon Redwood, FRCP, and Martyn Thomas, FRCPFrom t
Hosp
Disclos
cal, a
Edwa
comm
Read a
Surg
Receive
for pu
Address
Surge
Bridg
0022-52
Copyrig
http://dx
A
C
DObjective: Transcatheter valve-in-valve is an accepted treatment in high-risk patients with degenerative stented
bioprostheses in the aortic position. Experience in treating stentless valves is, however, limited. Our aim was to
determine the feasibility and single-center outcome of balloon expandable SAPIEN valve placement in degen-
erated stentless aortic valve bioprostheses.
Methods: From February 2010 to January 2014, 10 patients with failing stentless bioprostheses underwent
transcatheter aortic valve implantation using the Edwards SAPIEN transcatheter heart valve (SAPIEN, SAPIEN
XT, and SAPIEN 3) at our institution. Seven patients had valve failure due to regurgitation and three to stenosis.
The mean age was 73.3  15.0 years. The mean logistic EuroSCORE was 31.8  20.3, and the Society of
Thoracic Surgeons score was 7.6  5.4.
Results: Technical success was achieved in 9 of 10 patients. One patient required immediate placement of a
second valve owing to low placement of the first. Two intraoperative complications developed that needed addi-
tional procedures. One patient underwent immediate repair of a right ventricular perforation from a pacing lead,
the other, reexploration for epicardial bleeding. No deaths occurred. The median length of stay was 8.5 days
(range, 3-44). The mean follow-up was 8.1 months (range, 1-21). No late reoperations or reinterventions
were required.
Conclusions: Transcatheter aortic valve implantation after previous stentless aortic valve replacement is
technically demanding but a safe and feasible approach. The early results were excellent, with consistent
improvement in hemodynamics. Prospective long-term follow-up in larger series is needed to evaluate this
technique further. (J Thorac Cardiovasc Surg 2014;148:917-24)Transcatheter aortic valve implantation (TAVI) has emerged
as a viable treatmentmodality for patients with severe native
aortic valve stenosis and multiple comorbidities that would
typically preclude them from surgery.1,2 The expanding
indications have led to the use of transcatheter heart valves
(THVs) to treat stented bioprosthetic aortic valves that are
failing owing to either stenosis or regurgitation.3,4
During a valve-in-valve (VIV) procedure with a stented
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The Journal of Thoracic and Cafor the THV; hence, the procedure can be performed with
relative ease.5,6 In stentless valves, the lack of a stent
frame and sewing ring results in the absence of radiopaque
markers to allow VIV positioning. Moreover, different
sewing techniques and the proximity to the coronary ostia
can make the VIV procedure challenging.7 Furthermore,
the mechanism of failure of this valve type has typically
been cusp perforation or prolapse leading to regurgitation,
which could make locating the annular plane for correct
positioning difficult.7-9 These factors can amount to a
greater incidence of malposition, embolization, and
coronary obstruction during VIV compared with the VIV
procedure in the stented bioprosthesis.9 Choosing the cor-
rect type and size of the THV device is also important.
THVs are available either as balloon expandable or self-
expandable valves. There is currently a stronger inclination
to use the self-expandable THV with a nitinol frame when
performing VIV in a stentless bioprosthesis.
We report the feasibility of implanting a balloon
expandable THV, the successful early outcomes of VIV
for degenerated stentless biological aortic valve prostheses,
and discuss the technical considerations in planning and
performing such cases.rdiovascular Surgery c Volume 148, Number 3 917
Abbreviations and Acronyms
ID ¼ internal diameter
TA ¼ transapical
TAVI ¼ transcatheter aortic valve implantation
TEE ¼ transesophageal echocardiography
THV ¼ transcatheter heart valve
VIV ¼ valve-in-valve
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Patients
From February 2010 to January 2014, we performed 33 VIV procedures
for aortic bioprosthetic degeneration using the Edwards SAPIEN valve
(Edwards Lifesciences, Irvine, Calif). Of these 33 patients, 10 (30%)
had previously undergone placement of a stentless aortic bioprosthesis: 6
homografts, 1 Toronto SPV (St Jude Medical, St Paul, Minn), 1 Freestyle
root (Medtronic Inc, Minneapolis, Minn), 1 O’Brien (Cryolife, Kennesaw,
Ga), and 1 Pericarbon Freedom stentless valve (Sorin, Saluggia, Italy;
Table 1). The mean patient age was 73.3  14.0 years (range, 43-90). Of
the 10 patients, 7 were men and 3 were women. The mode of presentation
was either severe aortic valve regurgitation (n ¼ 7) or stenosis (n ¼ 3). Six
patients presented in New York Heart Association class IV. The mean
interval from the previous aortic valve procedure was 14.1  6.4 years
(range, 7-27). Two patients had undergone>1 previous valve replacement.
The mean logistic EuroSCORE and Society of Thoracic Surgeons score
were calculated. The logistic EuroSCORE was 31.2  19.0, and the
mean Society of Thoracic Surgeons score was 7.0  5.2. The risk of
conventional open aortic valve replacement was evaluated by a multidisci-
plinary team comprised of cardiac surgeons and cardiologists.
Methods
The preoperative diagnostic workup and routine postoperative care have
been previously described in detail.10 The previous operative notes were
consulted when available to obtain details of the type of valve implanted,
valve size, and surgical technique used. A preoperative transesophageal
echocardiogram (TEE) was performed in all patients to determine the exact
aortic annular diameter. A noncontrast-enhanced computed tomography
scan was used to identify and determine the presence of calcification in
the aortic annulus. A single valve type, the Edwards SAPIEN heart valve
(Edwards Lifesciences), was used in our series. The SAPIEN valve is a
balloon expandable THV. We have used all 3 iterations of this device, de-
pending on availability (ie, SAPIEN [steel frame], SAPIEN XT [cobalt
chromium frame], and, recently, SAPIEN 3 [cobalt chromium frame]).
Depending on the pre- and intraoperative measurements, either a 23-mm
or 26-mm device was implanted. The procedures were all performed in a
cardiac catheterization laboratory by a combined team of cardiac surgeons,
cardiologists, and anesthesiologists. A perfusionist was always present
with a primed cardiopulmonary bypass machine. The approach for TAVI
was either transfemoral or transapical (TA). The approach chosen was
dependent on the team’s preference after a review of the preoperative
workup findings. The TA approach was preferred when the size of the
femoral arteries was not suitable for transfemoral access. In 1 case, a TA
approach was preferred because the patient had a previously placed me-
chanical mitral prosthesis. The techniques for both approaches have been
previously described in detail.11,12 The size of the new valve to be
implanted was determined according to the internal diameter (ID) of the
annulus measured using transthoracic echocardiography and
intraoperative TEE. In valves other than homografts, the ID of the
prosthesis available from published charts was also used as a guide.13 A
size 23-mm SAPIEN valve was used if the ID of the annulus was 18 to918 The Journal of Thoracic and Cardiovascular Surg20 mm, and a 26-mm valve was used for a 22- to 24-mm annulus. In the
case of a borderline annulus, such as one with an ID of 21 mm, a larger
prosthesis (26-mm SAPIEN) was preferred if the leaflets were not bulky
and circumferential annular calcification was minimal. Simultaneous fluo-
roscopic, angiographic, and TEE imaging was routinely used to guide the
precise level for valve deployment. Balloon dilatation of the degenerated
valve before insertion of the prosthesis was not undertaken. Slow, gradual
inflation of the valve balloon was undertaken in contrast to the rapid valve
deployment sometimes seen. Implantation was performed during a short
run of ventricular rapid pacing. In 3 cases, a guidewire was placed in the
left main stem ostium to provide a landmark during deployment, because
it was impossible to determine the correct level of the aortic annulus owing
to severe regurgitation (Figure 1, A). Aortography and TEE assessment
were used to determine the correct placement and function of the SAPIEN
valve immediately after implantation (Figure 1, B). Special attention was
also given to the patency of the coronary arteries. The patients were fol-
lowed up closely postoperatively in accordance with the requirements of
our on-site registry. This included patient interviews, clinical examination,
and follow-up echocardiography. The complications are presented in
accordance with the Valve Academic Research Consortium-2 criteria.14
Statistical Analysis
Continuous variables are presented as the mean  standard deviation
and dichotomous or nominal variables as numbers and percentages. Stu-
dent’s t test was used to determine statistical significance, with an a of
0.05 for the parametric data set. Statistical analyses were performed using
the Statistical Package for Social Sciences, version 17.0, for Windows
(SPSS Inc, Chicago, Ill).RESULTS
Operative Course
Of the 10 patients, 9 required only 1 device implantation,
with 1 patient requiring an immediate second SAPIEN
implant after low placement of the first valve. The low
placement had resulted owing to difficulty visualizing the
level of the annulus using angiography because of severe
aortic regurgitation (Figure 1, C-E). One intraoperative
complication that required an additional procedure. The pa-
tient experienced a right ventricular perforation from the
transvenous pacing wire used during the procedure. This
was immediately diagnosed as pericardial effusion using
TEE and was repaired without the use of cardiopulmonary
bypass. This happened during a TA procedure in a patient
with minimal intrapericardial adhesions. In 5 patients, a
SAPIEN size 26-mm valve was implanted and in 5, a size
23-mm valve was implanted. The first-iteration SAPIEN
valve was used in 3 patients, the SAPIEN XT in 6 patients,
and the SAPIEN 3 in 1 patient. The mean procedure time
was 86.7  27.6 minutes (range, 44-135). The mean fluo-
roscopy time was 11.1  4.7 minutes (range, 5.5-18). The
mean volume of contrast medium used during the procedure
was 148 mL (range, 80-260). After valve implantation, the
TEE-measured peak transvalvular gradient had decreased
from 33.6  17.6 mm Hg to 11.3  4.4 mm Hg (P<.05).
The TEE-measured mean transvalvular gradient had
decreased from 16  9.8 mm Hg to 8.0  4.8 mm Hg
(P ¼ .077). Of the 10 patients, 4 had grade I paravalvular
aortic regurgitation after implantation and 6 had eitherery c September 2014
TABLE 1. Stentless valve types and their implantation options
Valve name and manufacturer Implantation options
Homograft Full root, mini-root, subcoronary
Freestyle (Medtronic) Full root, mini-root, subcoronary
Prima Plus (Edwards Lifesciences) Full root, mini-root, subcoronary
Toronto root (St Jude Medical) Full root, mini-root
Shelhigh Bioconduit (Shelhigh) Full root
Toronto SPV (St Jude Medical) Subcoronary
CryoLife-O’Brien (Cryolife) Subcoronary
Elan (AorTech) Subcoronary
Shelhigh Superstentless (Shelhigh) Subcoronary
Biocor PSB/SJM (St Jude Medical) Subcoronary
Pericarbon Freedom (Sorin) Subcoronary
3F Aortic Bioprosthesis
(3F Therapeutics)
Subcoronary
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in the transvavular gradients on the immediate postopera-
tive transthoracic echocardiogram compared with the
transthoracic echocardiogram performed at 6 weeks of
follow-up. Important details of the procedure are summa-
rized in Table 2.
Postoperative Course
In the early postoperative course, 3 significant complica-
tions developed. One patient required reoperation for
venous bleeding from the epicardium after undergoing the
procedure by way of the TA approach (BARC type 3a as
per the Valve Academic Research Consortium criteria). A
second patient developed transient right-sided weakness,
which lasted for 48 hours and resolved completely. A third
patient developed acute kidney injury necessitating
temporary hemodialysis. No postoperative myocardial
infarctions, no indications for postoperative pacemaker
insertion, and no wound complications developed. The
median intensive care unit length of stay was 1 day (range,
0.5-13), and the median length of hospital stay was 8.5 days
(range, 3-44). All patients survived to 30 days. The mean
left ventricular ejection fraction was 45.4%  14.2%
preoperatively and 42.6%  18.5% at discharge
(P ¼ .77). Neither early nor late valve reinterventions or
open conversions were required. The mean follow-up wasFIGURE 1. SAPIEN valve implantation in stentless valve.White line indicates
arrow) to provide a landmark and can provide access to the left main artery. B,
implanted in a low position. D, Second SAPIEN valve positioned within the fir
The Journal of Thoracic and Ca8.1 months (range, 1-21). At the last follow-up point, all
10 patients were alive.
DISCUSSION
With an improvement in life expectancy and lower age at
which patients opt for a bioprosthetic valve, it is inevitable
that an increasing number of patients will present with bio-
prosthetic valve dysfunction.15 The operative mortality for
elective redo aortic valve surgery has been reported to range
from 2% to 7%; however, this percentage can increase to
>30% in high-risk patients.16 For this subset of patients,
a VIV procedure represents a less invasive alternative to
conventional redo surgery. Although a relatively new tech-
nology, VIV is now an acceptable treatment in high-risk pa-
tients with failed bioprosthetic valves.3-6 It is important for
the operator to be familiar with the type and characteristics
of the failing bioprosthesis for an optimal result.17
Bioprosthesis Types
Essentially, 2 types of bioprosthetic valves are available:
stented and stentless.13,18 In a stented bioprosthesis, either
the frame or sewing ring usually provides fluoroscopic
landmarks, which aid during the VIV procedure; also, the
frame or sewing ring provides a secure anchor to the THV
(Figure 2,A andB).17 Stentless valves, however, are not radi-
opaque, because they lack a frame and most also lack a
distinct sewing ring (Figure 2,C andD). Furthermore, regur-
gitation is a common mode of failure. These factors can
make the VIV procedure in stentless valves challenging.
However, we believe that the fibrosis induced by the sutures
used for its implantation will limit the distensibility and can
provide anchorage for the VIV. Also, unlike stented valves,
in which the presence of the stent frame, sewing ring, and
leaflet tissue mounted within the frame effectively reduces
the ID available for a VIV procedure, the stentless valves
have less effect on the ID and might allow a larger THV
implantation compared with a similar-size stented valve.13
Stentless Valve Types and Implantation Techniques
During the past 2 decades, a number of stentless valves
have become commercially available worldwide (althoughthe annular plane. A, A guide wire was placed in the left main artery (black
Postimplant aortogram after SAPIEN XT implantation. C, SAPIEN valve
st valve. E, Second SAPIEN valve implanted in the correct position.
rdiovascular Surgery c Volume 148, Number 3 919
TABLE 2. Summary of previous and new valve characteristics
Pt. no.
Original
prosthesis type
Interval since
last valve
implant (y) Size (mm)
Pathologic
type
SAPIEN
valve size (mm)
Postimplant aortic
regurgitation Complications
1 Homograft 15.3 26 AS 26, SAPIEN None Second SAPIEN implant
2 O’Brien Cryolife 17.3 23 AR 23, SAPIEN Trivial Acute renal failure
3 Homograft 13.3 26 AS 26, SAPIEN Trivial Bleeding
4 Homograft 27.3 24 AR 23, SAPIEN XT Mild None
5 Sorin Pericarbon stentless 6.6 23 23, SAPIEN XT Trivial Right ventricular tear repaired
on-table
6 Homograft 14.3 28 AR 26, SAPIEN XT Mild None
7 St Jude Toronto SPV root 9.7 25 AS 26, SAPIEN XT Mild Transient neurologic deficit
postoperatively
8 Homograft 9.3 22 AR 23, SAPIEN XT Trivial None
9 Freestyle Root 7 23 AR 23, SAPIEN XT Trivial None
10 Homograft 16 26 AR 26, SAPIEN 3 Mild None
Pt. no., Patient number; AS, aortic stenosis; AR, aortic regurgitation.
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Dsome have since been withdrawn from the market), and
each has specific recommendations regarding implantation
options (Table 1).
Unlike stented valves, stentless valves can be implanted
using 1 of 3 techniques:
1. Subcoronary implantation (Figure 3, A)
2. Full root replacement (Figure 3, B)
3. Mini-root or inclusion technique (Figure 3, C).
From the perspective of performing a VIV TAVI, it is
essential to confirm the method of implantation, because
the choice can influence the risks and success, as discussed
in the following sections.
Risk of Coronary Obstruction
Coronary obstruction is an uncommon, but well-known,
complication after a VIV procedure.19 The risk is substan-
tially greater for stentless valves than for stented valves.9,19
This is related to the valve design. In most stented valves,
the leaflets will be sutured within the stent frame; hence,
even when pushed out with a THV, a gap will be present
between them and the coronary ostia (Figure 4, A). In the
subcoronary and mini-root techniques, the suture line will
be in close proximity to the coronary ostia. With no stent
frame present, the chance of coronary obstruction is greaterFIGURE 2. Types of bioprosthetic aortic valves. A, Stented valve example (H
strating the fluoroscopic appearance. C, Stentless valve example (Freestyle valv
demonstrating radiolucent characteristics.
920 The Journal of Thoracic and Cardiovascular Surgafter VIV, because the leaflets can be easily pushed to block
the coronary ostia (Figure 4, B). In contrast, during full root
replacement, the site of implantation of the coronary but-
tons will vary; however, essentially, the end result will
mimic a native aortic root, which could reduce the chance
of coronary obstruction after a VIV procedure (Figure 4,C).
The proximity of the suture line to the coronary ostia and
bulky calcified leaflets should alert the operator. The former
can be confirmed by aortography and later by echocardiog-
raphy. If the risk is anticipated to be high, it would bewise to
place a guidewire in the coronary ostia, such as in 2 of our
cases, and also to prepare the cardiopulmonary bypass cir-
cuit. One can use balloon aortic valvuloplasty with aortic
root contrast injection to diagnose this problem before pro-
ceeding to THV implantation.
THV Sizing and THV Type
Valve embolization has also been reported with greater
frequency with stentless valves than with stented valves.9
A part of the problem is assessing the true ID of the stentless
valves. Unlike the stented valves, in which the geometry
and dimensions of the valve are maintained after implanta-
tion and, hence, the ID and true ID can be obtained from
published charts, the final dimensions of the stentless valves
can vary, depending on the native root dimensions andancock 2) demonstrating its structure. B, Stentless valve example demon-
e) demonstrating its structure. D, Stentless valve example (Freestyle valve)
ery c September 2014
FIGURE 3. Types of stentless valves and techniques of implantation. A, Subcoronary implantation. B, Full root implantation. C, Mini-root implantation.
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roots can be used as a reference, but the final ID of stentless
valves will be influenced by the suturing technique and
diameter of the native root in which it is implanted. Homo-
grafts have historically been one of the most frequently used
stentless valves. Sizing of the homograft has never been
standardized and after implantation can vary from the initial
size. Hence, it is best to compliment these measurements
with computed tomography or 3-dimensional TEE. We
based our final decision on sizing intraoperatively using
3-dimensional TEE.20
The THV is anchored by virtue of oversizing.1,2 Unlike
when performing TAVI in the case of a native calcified
aortic valve or stented bioprosthesis, we erred on the side
of greater oversizing than usual. We believe this was
essential and safer in this setting for the following 3
reasons. First, the chance of coronary obstruction was less
than in a native valve case, because regurgitation and torn
leaflets were the major etiologies of failure. Second, the
risk of annular disruption was less. Finally, more secure
anchoring could be obtained. Hence, a 23-mm SAPIEN
valve was used for an aortic annulus diameter of 18 to 20
mm and a 26-mm valve for a 22- to 24-mm annulus. In
the case of a borderline annulus, such as 21 mm, a larger
prosthesis (26-mm SAPIEN) was preferred if the leaflets
were not bulky and circumferential annular calcificationFIGURE 4. Relationship of coronary ostia and bioprosthesis. A, Stented valve
suture line). C, Cross-section of stentless valve subcoronary implantation demon
arrow). D, Stentless valve replaced as full root, with suture line (large arrow) at
(small arrow).
The Journal of Thoracic and Cawas minimal. We believe that this degree of ‘‘oversizing’’
was essential to achieve secure anchoring of the device
and was a key factor contributing to the technical success
of the procedure in those patients with primary aortic
regurgitation.
Both balloon and self-expandable THVs have been used
to treat stentless valves and opinion might favor nitinol-
based devices.3,6,9 However, this has no scientific basis,
and we have exclusively used balloon expanded THVs.
As mentioned, stentless valves can function similar to a
native aortic valve but still have bulk, suture line, and
calcification sufficient to provide an anchor for any THV.
However, future valve designs with which one can
implant, check coronary flow, and, if necessary, retrieve
might be more suitable for this indication.
Prosthesis Positioning
Once again, the incidence of malpositioning and related
complications has been much greater during VIV proce-
dures with a stentless valve.6,9 The absence of
fluoroscopic markers and aortic regurgitation, when
present, can make it difficult to identify the annular plane.
In our first patient, we deployed the valve low, because
we were using a rapid inflation technique at that time and
did not use coronary wires. To maximize precise
deployment, we now routinely perform slow and gradual. B, Stentless valve replaced as subcoronary implantation (arrow points to
strating proximity of the suture line (large arrow) and coronary ostia (small
the level of annulus and the coronary ostia have been reimplanted higher up
rdiovascular Surgery c Volume 148, Number 3 921
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during a single short phase of rapid ventricular pacing. At
the same time, we also perform continuous contrast
injection at the level of the aortic root until the prosthesis
has been at least half deployed. We have also found that
placing a guidewire in left main or right coronary artery
(Figure 1, A) has occasionally been invaluable (3 cases in
our series) in providing us with a landmark for valve
deployment. This has been particularly useful in cases in
which severe aortic regurgitation precluded us from obtain-
ing a satisfactory root angiogram and/or we had difficulties
in obtaining good views of the annulus using TEE.
Other Technical Considerations
First, the surgical details of the bioprosthesis such as the
valve type and size and method of implantation should be
obtained because they are of paramount importance for rea-
sons we have highlighted.
Second, it is essential to rule out infective endocarditis in
any patient presenting with aortic regurgitation in the
setting of a previously placed stentless aortic valve. It
should not be assumed that the cause of the regurgitation
is primary leaflet degeneration.
Third, we do not routinely perform balloon aortic valvu-
loplasty of the degenerated valve before insertion of the
prosthesis unless the possibility of coronary obstruction is
a very great.
Finally, we believe that the surgical approach for access
should be highly individualized after a thorough review of
the preoperative clinical examination and radiographic
investigation (which includes a full computed tomography
aortogram at our center) findings. In the present series, we
performed the procedure using either a transfemoral or
TA approach. However, transaortic access has also been
used for the VIV procedure.21
CONCLUSIONS
We have demonstrated that the TAVI procedure after
previous stentless aortic valve replacement and that the
valve-in-stentless-valve concept is technically feasible and
safe using a balloon expandable SAPIEN THV. The early
results showed improvement in hemodynamics and
symptom amelioration. Larger studies with longer follow-
up are needed to confirm our results.
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Dr A. Pieter Kappetein (Rotterdam, The Netherlands).
Dr Bapat, congratulations on a great report, and again, it is another
excellent contribution from your group for a very complex patient
population.ery c September 2014
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DThe valve that you implanted actually concerns a variety of bio-
prostheses, 6 homografts, 1 Toronto valve, 1 Freestyle valve, 1
O’Brien valve, and 1 Pericarbon valve, and the mean age of those
patients was 73 years. The mean interval from the previous aortic
valve procedure to the implantation of the bioprosthesis or homo-
graft was 14 years, but it concerns a wide range, from 7 years to 27
years. The groups were rather small; thus, I assume you could not
determine a difference between the homografts and xenografts, but
perhaps you could.
Now that VIV procedures are possible, we will see much larger
series of patients with a failing bioprosthesis. If you ask the
average surgeon how many failing bioprostheses they operate on
per year, they will probably say 1 or 2 or 3, depending on the
size of their practice. Last year at EuroPCR, a series was presented
of 450 patients with a failing bioprosthesis, and the mean interval
between implantation of the bioprosthesis and the VIV procedure
was only 9 years. If we study our surgical data, we often see series
with a follow-up period of 20 years and 95% freedom from
reoperation.
So, the question is, what is the reason that we have always
believed that bioprosthetic valves can last 20 years and that
now we actually see large series of patients undergoing a VIV pro-
cedure at a relatively low average age, as you pointed out, 73 years,
but also, that the interval between implantation of the bioprosthesis
and the VIV procedure is not as long as 20 years? Do you think it is
justified, to lower the age at which we implant a bioprosthesis now
that we have the possibility of a VIV procedure?
My last question, do you think that one of the other transcatheter
prostheses, for example a self-expandable valve, might have an
advantage, with a lower risk of coronary obstruction?
Thank you very much again for an excellent presentation.
Dr Bapat. Thank you very much, Dr Kappetein, for your excel-
lent questions.
I think my view is that the reason we are seeing early failure
rates or less durability data in terms of duration is because we
are implanting them in younger patients. I think the series that
showed that the durability of the valves would be 20 years or so
was more historical in which the implantation age for a bio-
prosthesis was 70 plus years.
Today, in most of my practice, I rarely implant a mechanical
valve because even a patient of 50 years requests a tissue valve.
That might explain why we are seeing patients returning slightly
earlier than in the past.
Dr Kappetein. If I could interrupt. If one implants a bio-
prosthesis in a 50-year-old patient, and the mean follow-up for
freedom from reoperation is 15 years, one will need to do a VIV
procedure in a 65-year-old patient. For the transcatheter heart
valves, we do not know the durability in a 65-year-old patient,
and, if the valve lasts, for example, 10 years, one will have a
75-year-old patient in whom you need to perform a valve in a valve
in a valve procedure.
Dr Bapat. I think that is a very good question, and I tend to
match, or my group tends to match, the life expectancy of the pa-
tient to the treatment. My view regarding such patients, the specific
example you gave, would be to reoperate in the patient at 65 years
and then perform a VIVat age 75 or 80 years when he comes, if he
survives to that age, rather than perform a VIV procedure at 65
years and then reoperate when he is 80 years old. However if hisThe Journal of Thoracic and Calife expectancy is shorter because of comorbidities, I think it would
be a reasonable to perform a VIV procedure at age 65 years.
So, I think we need to match the patient’s survival to the type of
treatment we have, and that has been our view at present.
Dr Kappetein. Right.
Dr Bapat. Regarding your third question, which is other de-
vices, yes, a nitinol platform or valves such as the CoreValve
and Portico would definitely have some advantage because they
are self expandable and hence have been favored for scentless
valves.
However, I think positioning a nitinol self-expanding valve be-
comes very tricky because these are longer devices. Also, with
aortic regurgitation, you might not achieve accurate landing in
contrast to a balloon expandable valve, because most balloon
expandable valves are implanted under pacing.
The main reason we presented our report was because of the
fear that a balloon expandable valve needs a lot of anchor, such
as calcium, and might not be suitable for stentless valves at all.
However, I think the fibrosis and suture material provides enough
anchor to implant these valves.
DrKappetein. Thank you verymuch. Do you think that most of
our knowledge of the durability of bioprosthesis is based on reop-
eration-free data and not freedom from valve failure, which are 2
distinct entities.
My impression has been that we see more patients with a failing
bioprosthesis because we have the possibility of a VIV with trans-
catheter heart valve implantation. We might have overestimated
the durability of our bioprosthetic valves.
Dr Bapat. I think I completely agree with you.
Dr Kappetein. Okay. Thank you very much.
Dr Danny Dvir (Vancouver, British Columbia, Canada). Yes.
Dr Kappetein, we were very surprised in the global registry to
see that the median interval to failure between surgery and the
VIV procedure was only 9 years. We were really in shock when
we saw that finding.
The stentless valves do fail, just as you showed, Dr Bapat, really
longer than the stented, 12 to 13 years versus 8 to 9 years.
However, I must say that when we are talking about decreasing
the cutoff age between implantation of a mechanical valve to
bioprosthetic valve, thinking of performing a VIV procedure in
the future, we must understand that some limitations exist to the
VIV field. We have the left main obstruction, the malpositioning,
and, probably the most problematic, the elevated postprocedure
gradients.
So when we are talking about implantation of a bioprosthetic
valve, thinking of performing a VIV procedure in the future, we
should understand that the surgical procedure has a great amount
of impact and influence on the success of performing VIV in the
future. The surgical valve size has a great amount of impact.
The position of the coronaries, the relationship between the surgi-
cal valve and the coronaries, will have a great amount of impact, as
will the type of the surgical valve.
Dr Bapat. I think what I must point out, Dr Kappetein, is that
these are a very high-risk select group of patients that have under-
gone the VIV procedure. Fit patients whowere at medium risk and,
relatively, even at high risk, have undergone open surgery.
Dr Hans-Joachim Sch€afers (Homburg/Saar, Germany).
Perhaps just 1 quick question from me and a short answer.rdiovascular Surgery c Volume 148, Number 3 923
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DThe youngest patient in your group was 43 years old. Given the
known uncertainty about the durability of these transcatheter
valves, what should be the lowest age at which we would seriously
consider transcatheter replacement?
Dr Bapat. I think you should consider, for example, in a young
woman who wants to have children, and she does not want to take924 The Journal of Thoracic and Cardiovascular Surganticoagulation. I would implant a transcatheter valve, let her
complete her family, and then reoperate.
Dr Sch€afers.Otherwise? That is a special situation. Otherwise?
Dr Bapat. If we think that the life expectancy of the patient will
be less than the durability of the transcatheter valve, we would
implant a transcatheter valve even in younger patients.ery c September 2014
